ImmuPharma (IMM) News Today GBX 17.51 +3.53 (+25.27%) As of 12:44 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock Why Is ImmuPharma Up Today?Toggle Visibility of Why Is ImmuPharma Up Today?ImmuPharma plc (LON:IMM) shares have surged over the past two trading sessions, with intraday gains peaking at 28.8% on September 13 and around 19–20% on September 12. Trading volumes have exploded—recently topping 65.6 million shares versus a 9-day average of 8.4 million—yet no company‐sponsored announcements (such as trial data releases, licensing deals or financing rounds) have been made public. Investors appear to be front‐running a potential catalyst, but the lack of confirmed news leaves the rally’s sustainability in question. Positive Sentiment: 28.8% intraday jump on September 13, driven by heavy volume and renewed investor interest. ImmuPharma Stock Price Up 28.8% – Here’s What Happened Positive Sentiment: Earlier 20.6% surge on September 12 suggests a multi‐day accumulation phase. ImmuPharma Trading Up 20.6% – Time to Buy? Neutral Sentiment: No official update on ImmuPharma’s lead asset Cobitolimod or any corporate transaction to explain the rally. Negative Sentiment: High volatility raises risk for short‐term traders; fundamentals remain challenging with ongoing losses and a negative EPS for the year. Posted 1h agoAI Generated. May Contain Errors. IMM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period ImmuPharma (LON:IMM) Trading 28.8% Higher - Still a Buy?1 hour ago | marketbeat.comImmuPharma (LON:IMM) Trading 28.8% Higher - Here's Why1 hour ago | marketbeat.comImmuPharma (LON:IMM) Trading Up 28.8% - Here's What Happened1 hour ago | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 28.8% - Should You Buy?4 hours ago | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 28.8% - Here's What Happened5 hours ago | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 28.8% - Time to Buy?September 15 at 8:39 AM | marketbeat.comImmuPharma (LON:IMM) Trading 28.8% Higher - What's Next?September 15 at 6:25 AM | americanbankingnews.comImmuPharma (LON:IMM) Stock Price Up 28.8% - What's Next?September 15 at 4:26 AM | americanbankingnews.comImmuPharma (LON:IMM) Trading Up 28.8% - Time to Buy?September 15 at 4:20 AM | marketbeat.comImmuPharma (LON:IMM) Trading 28.8% Higher - Here's What HappenedSeptember 15 at 4:20 AM | marketbeat.comImmuPharma (LON:IMM) Trading 28.8% Higher - Time to Buy?September 15 at 3:51 AM | americanbankingnews.comImmuPharma (LON:IMM) Trading Up 20.6% - Time to Buy?September 14 at 12:11 PM | marketbeat.comImmuPharma (LON:IMM) Trading 19.8% Higher - Time to Buy?September 14 at 12:11 PM | marketbeat.comImmuPharma (LON:IMM) Trading Up 18.6% - Should You Buy?September 14 at 9:53 AM | marketbeat.comImmuPharma (LON:IMM) Shares Up 18.6% - Should You Buy?September 14 at 9:53 AM | marketbeat.comImmuPharma (LON:IMM) Shares Up 20.1% - Here's What HappenedSeptember 14 at 8:19 AM | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 19.8% - Should You Buy?September 14 at 8:19 AM | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 19.3% - What's Next?September 14 at 7:17 AM | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 18.6% - Should You Buy?September 14 at 3:43 AM | americanbankingnews.comImmuPharma (LON:IMM) Trading Up 19.3% - What's Next?September 14 at 2:51 AM | americanbankingnews.comImmuPharma (LON:IMM) Trading Up 4.6% - What's Next?September 13 at 7:41 AM | marketbeat.comImmuPharma (LON:IMM) Shares Down 7.6% - Here's What HappenedSeptember 13 at 6:39 AM | marketbeat.comSMALL CAP MOVERS: Lupus drug patent lights up the marketSeptember 12 at 12:39 PM | msn.comImmuPharma (LON:IMM) Trading Up 13.9% - Here's What HappenedSeptember 12 at 8:25 AM | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 13.9% - Still a Buy?September 12 at 8:25 AM | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 17.2% - Here's WhySeptember 12 at 7:38 AM | marketbeat.comImmuPharma (LON:IMM) Trading 11.5% Higher - Still a Buy?September 12 at 6:52 AM | marketbeat.comImmuPharma (LON:IMM) Trading Up 22.1% - What's Next?September 12 at 6:52 AM | marketbeat.comImmuPharma (LON:IMM) Trading Up 34.1% - Still a Buy?September 12 at 6:29 AM | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 34.1% - Should You Buy?September 12 at 6:29 AM | marketbeat.comImmuPharma (LON:IMM) Trading Up 34.1% - Time to Buy?September 12 at 5:17 AM | marketbeat.comImmuPharma (LON:IMM) Trading Up 34.1% - Here's What HappenedSeptember 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Shares Up 34.1% - Should You Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Trading 34.1% Higher - What's Next?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 34.1% - Here's What HappenedSeptember 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Shares Up 34.1% - Here's WhySeptember 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Shares Up 34.1% - Time to Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Trading 34.1% Higher - Still a Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Trading 34.1% Higher - Time to Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 34.1% - Still a Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Shares Up 34.1% - Still a Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Trading 34.1% Higher - Here's What HappenedSeptember 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Shares Up 33.9% - Still a Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 24.1% - Should You Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Stock Price Up 25.3% - Should You Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Trading Up 29% - Time to Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Trading 14.1% Higher - Time to Buy?September 11, 2025 | marketbeat.comImmuPharma (LON:IMM) Shares Up 56.4% - Time to Buy?September 9, 2025 | americanbankingnews.comSMALL CAP MOVERS: Breakthrough week for Britain's pharma minnowsSeptember 5, 2025 | msn.comImmuPharma (LON:IMM) Stock Price Down 8.4% - Should You Sell?September 5, 2025 | americanbankingnews.com Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMM Media Mentions By Week IMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMM News Sentiment▼0.240.94▲Average Medical News Sentiment IMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMM Articles This Week▼441▲IMM Articles Average Week Get the Latest News and Ratings for IMM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for ImmuPharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies HVO News SBTX News HEMO News FUM News SAR News POLB News AREC News FAB News IXI News OPTI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:IMM) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
